Predictors of mortality for dermatomyositis patients positive with anti-melanoma differentiation-related gene 5 and optimal treatment
Authors' conclusion
Advanced age, skin ulcer, lymphopenia, anti-Ro52 antibody and higher levels of LDH, CRP and GGO score increase the risk of early death for MDA5-DM, while prophylactic use of SMZ Co is protective.
Study context
- Population
- Patients with newly onset anti-MDA5-DM, June 2018 to October 2021, single centre5 lost to follow-up
- Participants
- 214 patients
- Exposure
- Five groups by initial treatment regimen
- Outcome
- Mortality
- Follow-up
- 6 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Died during 6-month follow-up
63 patients
30.14%
Observational data: associations, not effects.
Secondary outcomes
Remission · 6 months
- Achieved remission
- 112 patients (53.59%)
Mortality in rapidly progressive interstitial lung disease (RPILD) (subgroup)
- Better response to triple glucocorticoids (GC) + calcineurin inhibitors (CNI) + CYC or triple GC + CNI + tofacitinib (TOF)
Safety
Serious infection · 6 months
- Experienced serious infection
- 52 patients (24.88%)
Original publication
Predictors of mortality for dermatomyositis patients positive with anti-melanoma differentiation-related gene 5 and optimal treatment. Clin Exp Rheumatol. Published 29 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →